SGLT2 inhibitors have a unique mechanism of action and are independent of insulin or the degree of insulin resistance; therefore, they could be combined with any class of antidiabetic agents at any stage of disease progression in type 2 diabetes mellitus19, 20. This evidence concerns the gene INS and type 2 diabetes mellitus.